Aelix and Bionaturis receive funding for the development of vaccines

Integral service around a transaction
BY : Diego GutiérrezJanuary Thu, 2016
The development of new vaccines is a long and costly process in which it is often difficult to find funding, due to the uncertainty in the sector. However, it is necessary in order to find solutions to improve our health. This week we have learned that two companies active in this sector, Aelix and Bionaturis, have received funding.



Aelix therapheutics receives €11M investment round

Aelix Therapeutics is a spin off from HIVACATthe Catalan programme for the development of effective vaccines against HIV, integrated within the IrsiCaixa AIDS Research Institute.

Investment has been led by  Ysios BioFund II Innvierte, the second fund managed by Ysios Capital, and has counted with the participation of Caixa Capital Risc, the division of capital risk of "la Caixa", and Johnson and Johnson Innovation - JJDC Inc., an international corporate investor.

"The incorporation of international corporate partners with expertise in virology and vaccines is a great advantage for Aelix, which, in addition to being funded, will benefit from the knowledge provided by these corporations," says Diego Gutierrez of Aelix. Abra-Invest.

The funds raised will be used to complete the team and advance the development of its lead product, the HTI immunogen, as a therapeutic vaccine for the treatment of HIV infection. Clinical trials will begin at the end of 2016 with a study safety studies in people who do not carry the virus, and will subsequently include efficacy studies in infected patients.

This is Aelix Therapeutics' first round, with which it expects to cover its financial needs until 2019. Once the results are known, several options will be opened up, such as "a new capital increase or allying with a large pharmaceutical company that allows the product to be distributed to other countries through its logistics and sales network," explains Jordi Naval.

Bionaturis receives CDTI funding under the Euroestars programme

Bionatoris has received €18,4846 under the European Eurostars programme for participation in the CerviPro initiative, which develops a cost-effective vaccine to treat cervical cancer in developing countries. The initiative is led by the German company BioEnergy GmbH & Consultant and also involves the German Cancer Research Center.

With this project, Bionaturis Group participates in an alternative strategy to produce the drug in a cost-effective way making it accessible to the regions where it is most needed. Within the project, the Bionaturis Group will be in charge of the development of the purification of the vaccine as well as its analytical characterisation.

If you are looking for financing, please contact us. Abra-Invest has an expert team of alternative financing experts at your disposal. Call us on + 34 946424142 or fill in the contact form. 


Other posts that may interest you

Spanish biotech companies go public

October 2015: Funding for the biotech sector: InnoUp Farma and Oryzon Genomics and Mind The Byte

Spanish biotech companies internationalise: Artax Biopharma, PharmaMar and Mind The Byte

The M&A Professionals

Meet our services



Do you want to be up to date?


Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?